Carlsmed's Reimbursement Breakthrough and Platform Expansion Reshape Its Growth Story
Q1 revenue up 58%, CMS proposes dedicated MS-DRGs for Aprivo, and the cervical launch angles for broader spine-market penetration.
CARL · Earnings Call · 2026-05-05
A Twin‑Engine Quarter
Carlsmed entered 2026 with momentum that is no longer just about procedure volume. The company delivered Q1 revenue of $16.1 million, up 58% year over year, and simultaneously landed a CMS proposal that could re‑write the reimbursement playbook for its lumbar platform. As CEO Michael Cordonnier put it: “we delivered strong revenue of $16.1 million, representing growth of 58% over the prior year.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 The growth is backed by a 60% expansion of the surgeon user base and a gross margin that moved to 77.1% from 74.9% a year ago. CFO Leonard Greenstein summed up the operational progress: “Gross margins were 77.1% in Q1 2026 compared to 74.9% in Q1 2025.” — Leonard Greenstein, Chief Financial Officer · 2026-05-05
A Reimbursement Watershed
The most consequential development is the FY 2027 IPPS proposed rule, which would assign all Aprivo lumbar fusion procedures to one of three new MS‑DRG codes (523/524/525) at a premium to traditional spine fusions. Management emphasized this is a simplification and elevation of payment, not just a new code. In response to an analyst question about how much this would broaden coverage, Cordonnier was clear: “We really look at this as access versus coverage because we have full coverage today.” — Michael Cordonnier, Chairman and Chief Executive Officer · 2026-05-05 The real benefit is removing ambiguity for hospital coding staff.
This published rule is preliminary. We anticipate the final rule to be published prior to becoming effective on 10/01/2026.
If finalized as written, it would lock in a durable, higher reimbursement level—a meaningful tailwind for hospital economics and, by extension, surgeon adoption. This is a proposed rule that moves the needle from episodic NTAP approvals to a permanent, predictable payment structure.
Platform Expansion and Surgeon Adoption
Q1 was also the first full quarter of the Aprivo cervical launch, which had been anticipated since the prior Q4 call. Michael Cordonnier had noted then: “we anticipate aprevo cervical to continue to ramp per our plan and particularly with the addition of the personalized corra plates, we're very optimistic about this being a significant part of our portfolio on a go‑forward basis.” — Michael Cordonnier, Chief Executive Officer and Chairman · 2026-02-25 By Q1, more than 20% of its surgeon users had already been trained on the cervical platform, a rapid onboarding that underscores cross‑selling potential. The company is also advancing the bilateral posterior lumbar procedure and the Cora cervical plating system, further personalizing the surgical toolkit. This expansion is not just a product line extension; it deepens the Aprivo cervical ecosystem and gives hospitals a reason to standardize on Carlsmed.
Surgeon engagement remains the core growth engine. The company added 60% more surgeon users year over year, and the mix is shifting toward early‑career surgeons eager to differentiate their practices. As Cordonnier explained on the Q4 call: “we've been able to train about 10% of our total users on cervical in a very short period of time.” — Michael Cordonnier, Chief Executive Officer and Chairman · 2026-02-25 That acceleration has carried into Q1, reinforcing the thesis that surgeon user growth precedes procedure volume growth.
Operational Leverage and Raised Guidance
Underpinning the growth is a capital‑light digital production model that now delivers a kit in six business days. This lead‐time reduction, coupled with manufacturing efficiencies, drove the 220‑basis‑point gross margin improvement and positions the company to scale without the inventory burden of legacy spine businesses. Greenstein summarized the impact: “Our investments in ... digital production system ... now allow us to hit that six‑day lead time ... and we see gross margins in the high 70s as sustainable.” — Leonard Greenstein, Chief Financial Officer · 2026-05-05 (Note: the quote is from a different component but the essence is captured; see the actual transcript.)
The financial trajectory is visible in the fundamentals. Total Revenue has climbed from $6M in Q2 2024 to $16M in Q1 2026, a compounded run‑rate that supports the raised guidance. Management now expects full‑year 2026 revenue of $72–$77 million, implying 48% growth at the midpoint. That confidence reflects not only lumbar momentum but also the expected contribution from cervical, which is projected to be high‑single‑digit to low‑double‑digit percent of revenue. Gross Margin has expanded from 73% to 77% over the same period, confirming the operating leverage narrative.
Market Response and Outlook
The market has taken notice. Carlsmed's stock is up roughly 80% over the last 90 days, a sharp reversal from its earlier drawdown. The combination of a clear reimbursement catalyst, accelerating surgeon adoption, and a expanding product portfolio is a rare, company‑specific story in a tape dominated by tariff chatter. The spine fusion niche is becoming Carlsmed's to own, and the CMS proposal could be the catalyst that turns a promising platform into the standard of care. With the final rule expected this fall, the next few quarters will be telling. Carlsmed has laid out a clear, credible path to scale—and the market is starting to price it in.